Organon’s Asenapine Shows Less Weight Gain Than Zyprexa In Phase III Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Patients taking asenapine had approximately two-fold lower incidence of clinically significant weight gain; efficacy profile was similar to Lilly’s olanzapine.
You may also be interested in...
FDA Accepts NDA For Schering-Plough Antipsychotic Asenapine
Schering’s acquisition of asenapine developer Organon was completed Nov. 19; Dutch firm has previously reported positive data in comparison to J&J’s Risperdal and Lilly’s Zyprexa.
FDA Accepts NDA For Schering-Plough Antipsychotic Asenapine
Schering’s acquisition of asenapine developer Organon was completed Nov. 19; Dutch firm has previously reported positive data in comparison to J&J’s Risperdal and Lilly’s Zyprexa.
Organon Asenapine Study Shows Improved Effect On Negative Schizophrenia Symptoms Over Risperdal
Patients treated with asenapine also experienced less weight gain and lower levels of prolactin, a signal associated with improved sexual side effects.